Skip to main content
Top
Published in: International Journal of Hematology 5/2015

01-11-2015 | Original Article

Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration–time curve in pediatric hematopoietic stem cell transplant recipients

Authors: Erika Watanabe, Takuro Nishikawa, Kazuro Ikawa, Hiroki Yamaguchi, Takanari Abematsu, Shunsuke Nakagawa, Koichiro Kurauchi, Yuichi Kodama, Takayuki Tanabe, Yuichi Shinkoda, Kazuaki Matsumoto, Yasuhiro Okamoto, Yasuo Takeda, Yoshifumi Kawano

Published in: International Journal of Hematology | Issue 5/2015

Login to get access

Abstract

Optimizing systemic busulfan exposure, the area under the concentration–time curve (AUC), improves the outcomes for hematopoietic stem cell transplantation (HSCT). The AUC is conventionally calculated using six plasma concentrations (AUC0–∞) drawn after the first of 16 intravenous busulfan doses given as a 2-h infusion every 6 h. The aim of the present study was to develop limited sampling strategies using three or fewer busulfan concentrations to reliably calculate AUC0–∞ in patients undergoing HSCT. We investigated the pharmacokinetics of busulfan 46 times in 29 pediatric patients receiving intravenous busulfan. Limited sampling strategies using one, two, or three plasma busulfan concentrations were developed by multiple linear regression that showed excellent agreement with AUC0–∞. In single-point sampling strategies, the AUC0–∞ predicted based on C6 (trough level: busulfan plasma concentration 6 h after the start of the infusion) was significantly correlated with, and not statistically different from, actual values as follows: AUC0–∞ = 2556.5 C6 + 320.9 (r 2  = 0.929, P < 0.0001, mean bias 0.282 %, precision 7.91 %). In contrast, the predicted AUCs derived from the other sampling single points did not meet the criteria. The trough level well correlated with actual AUC0–∞, suggesting that this time-point is acceptable for busulfan monitoring.
Literature
1.
go back to reference Hoy SM, Lyseng-Williamson KA. Intravenous busulfan in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Paediatr Drugs. 2007;9:271–8.CrossRefPubMed Hoy SM, Lyseng-Williamson KA. Intravenous busulfan in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Paediatr Drugs. 2007;9:271–8.CrossRefPubMed
2.
go back to reference Bredeson C, LeRademacher J, Kato K, Dipersio JF, Agura E, Devine SM, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013;122(24):3871–8.PubMedCentralCrossRefPubMed Bredeson C, LeRademacher J, Kato K, Dipersio JF, Agura E, Devine SM, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013;122(24):3871–8.PubMedCentralCrossRefPubMed
3.
go back to reference Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31–42.PubMed Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31–42.PubMed
4.
go back to reference Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225–30.PubMed Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225–30.PubMed
5.
go back to reference Michel G, Valteau-Couanet D, Gentet JC, Esperou H, Socié G, Méchinaud F, et al. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer. 2012;58(1):90–7.CrossRefPubMed Michel G, Valteau-Couanet D, Gentet JC, Esperou H, Socié G, Méchinaud F, et al. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer. 2012;58(1):90–7.CrossRefPubMed
6.
go back to reference Nagasawa M, Mitsuiki N, Ono T, Takagi M, Oda H, Yasuhara M, et al. Pharmacokinetic monitoring is still required for intravenous busulfan in SCT for small children. Int J Hematol. 2010;91(4):728–30.CrossRefPubMed Nagasawa M, Mitsuiki N, Ono T, Takagi M, Oda H, Yasuhara M, et al. Pharmacokinetic monitoring is still required for intravenous busulfan in SCT for small children. Int J Hematol. 2010;91(4):728–30.CrossRefPubMed
7.
go back to reference Sato M, Kako S, Matsumoto K, Oshima K, Akahoshi Y, Nakano H, et al. Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation. Int J Hematol. 2015;101(5):497–504.CrossRefPubMed Sato M, Kako S, Matsumoto K, Oshima K, Akahoshi Y, Nakano H, et al. Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation. Int J Hematol. 2015;101(5):497–504.CrossRefPubMed
8.
go back to reference Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des. 2008;14(20):1936–49.CrossRefPubMed Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des. 2008;14(20):1936–49.CrossRefPubMed
9.
go back to reference Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 2004;33(10):979–87.CrossRefPubMed Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 2004;33(10):979–87.CrossRefPubMed
10.
go back to reference Henner WD, Furlong EA, Flaherty MD, Shea TC, Peters WP. Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr. 1987;416:426–32.CrossRefPubMed Henner WD, Furlong EA, Flaherty MD, Shea TC, Peters WP. Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr. 1987;416:426–32.CrossRefPubMed
11.
go back to reference Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm. 1978;6(6):547–58.CrossRefPubMed Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm. 1978;6(6):547–58.CrossRefPubMed
12.
go back to reference Nishikawa T, Okamoto Y, Tanabe T, Shinkoda Y, Kodama Y, Higashi M, et al. Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation. Bone Marrow Transplant. 2010;45(3):602–4.CrossRefPubMed Nishikawa T, Okamoto Y, Tanabe T, Shinkoda Y, Kodama Y, Higashi M, et al. Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation. Bone Marrow Transplant. 2010;45(3):602–4.CrossRefPubMed
13.
go back to reference Okamoto Y, Nagatoshi Y, Kosaka Y, Kikuchi A, Kato S, Kigasawa H, et al. Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children. Pediatr Transplant. 2014;18(3):294–301.CrossRefPubMed Okamoto Y, Nagatoshi Y, Kosaka Y, Kikuchi A, Kato S, Kigasawa H, et al. Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children. Pediatr Transplant. 2014;18(3):294–301.CrossRefPubMed
14.
go back to reference Zao JH, Schechter T, Liu WJ, Gerges S, Gassas A, Egeler RM, et al. Performance of busulfan dosing guidelines for pediatric hematopoietic stem cell transplant conditioning. Biol Blood Marrow Transplant. 2015;21(8):1471–8.CrossRefPubMed Zao JH, Schechter T, Liu WJ, Gerges S, Gassas A, Egeler RM, et al. Performance of busulfan dosing guidelines for pediatric hematopoietic stem cell transplant conditioning. Biol Blood Marrow Transplant. 2015;21(8):1471–8.CrossRefPubMed
15.
go back to reference Takamatsu Y, Sasaki N, Eto T, Nagafuji K, Abe Y, Choi I, et al. Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation. Int J Hematol. 2007;86(3):261–8.CrossRefPubMed Takamatsu Y, Sasaki N, Eto T, Nagafuji K, Abe Y, Choi I, et al. Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation. Int J Hematol. 2007;86(3):261–8.CrossRefPubMed
16.
go back to reference Beri R, Chunduri S, Sweiss K, Peace DJ, Mactal-Haaf C, Dobogai LC, et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant. 2010;45(2):249–53.CrossRefPubMed Beri R, Chunduri S, Sweiss K, Peace DJ, Mactal-Haaf C, Dobogai LC, et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant. 2010;45(2):249–53.CrossRefPubMed
17.
go back to reference Spasojevic I, da Costa LR, Horwitz ME, Long GD, Sullivan KM, Chute JP, et al. Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry. Cancer Invest. 2012;30(9):679–82.PubMedCentralCrossRefPubMed Spasojevic I, da Costa LR, Horwitz ME, Long GD, Sullivan KM, Chute JP, et al. Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry. Cancer Invest. 2012;30(9):679–82.PubMedCentralCrossRefPubMed
18.
go back to reference Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol. 2006;57(2):191–8.CrossRefPubMed Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol. 2006;57(2):191–8.CrossRefPubMed
19.
go back to reference Dupuis LL, Sibbald C, Schechter T, Ansari M, Gassas A, Théorêt Y, et al. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies. Biol Blood Marrow Transplant. 2008;14(5):576–82.CrossRefPubMed Dupuis LL, Sibbald C, Schechter T, Ansari M, Gassas A, Théorêt Y, et al. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies. Biol Blood Marrow Transplant. 2008;14(5):576–82.CrossRefPubMed
20.
go back to reference Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815–50.CrossRefPubMed Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815–50.CrossRefPubMed
Metadata
Title
Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration–time curve in pediatric hematopoietic stem cell transplant recipients
Authors
Erika Watanabe
Takuro Nishikawa
Kazuro Ikawa
Hiroki Yamaguchi
Takanari Abematsu
Shunsuke Nakagawa
Koichiro Kurauchi
Yuichi Kodama
Takayuki Tanabe
Yuichi Shinkoda
Kazuaki Matsumoto
Yasuhiro Okamoto
Yasuo Takeda
Yoshifumi Kawano
Publication date
01-11-2015
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2015
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1853-6

Other articles of this Issue 5/2015

International Journal of Hematology 5/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine